MAM
iProspect India appoints Soham Bhagnari as AVP – Business Development
MUMBAI: iProspect India has appointed Soham Bhagnari as the associate vice-president (AVP) – business development. He will drive business expansion across the West region and operate out of Mumbai, reporting into iProspect India operations EVP Brijesh Munyal. He will be supported by AVP for new business Krishna Mothey from Mumbai.
Prior to iProspect India, Bhagnari has worked with Clique for five years as Director – Digital and Group M’s Mindshare in Mumbai. Before shifting base to Mumbai, he has spent the first four years of his career in Dubai, with stints at Wunderman and the Omnicom Group. He has worked across varied sectors such as banking, education, auto, entertainment, luggage and web publications in the past.
iProspect India CEO Vivek Bhargava said, “Soham’s poised to play an integral role in our overall business growth plans and his high proficiency is sure to add immense value to the organisation. We’re geared up to scale, especially in terms of the numbers and nature of our clientele – this is the start of exciting times ahead.”
“We’ve started taking steps in the right direction by building and investing in capabilities like video story-telling, content and creative to complement our existing performance and media buying capabilities. The larger picture is to make it a cornerstone of our growth! Post spending over 10 years in various facets of a continuously evolving medium, I understand the demands of the industry and its penchant for change,” Bhagnari added.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
